Products

Cas No.Product NameDescription
184025-19-2Ciproxifan maleateCiproxifan, Antagonists of H3-type histamine receptors exhibit cognitive-enhancing properties in various memory paradigms as well as evidence of antipsychotic activity in normal animals.
140462-76-6Olopatadine HydrochlorideOlopatadine HCl is a histamine blocker used to treat allergic conjunctivitis.
442-52-4ClemizoleClemizole is an H1 histamine receptor antagonist.
1238673-32-9UNC0321UNC0321 is a potent and selective G9a inhibitor with Ki of 63 pM, UNC0321 is the first G9a inhibitor with picomolar potency and the most potent G9a inhibitor to date.
1355326-21-4Mutant IDH1-IN-1Mutant IDH1-IN-1 is a potent mutant IDH1 R132H inhibitor with IC50 < 0.1 uM(A level in Patent); more bioactivity information in Patent WO2012009678A1.
1222800-79-4ML234ML324 is a potent JMJD2 demethylase inhibitor with demonstrated antiviral activity.
1431368-48-7GSK-LSD1 2HClGSK-LSD1 2HCl is an irreversible, and selective LSD1 inhibitor with IC50 of 16 nM, > 1000 fold selective over other closely related FAD utilizing enzymes (i.e. LSD2, MAO-A, MAO-B).
20187-55-7Bendazac
1802175-06-9CPI-360CPI-360 is a potent, selective,and SAM-competitive EZH1 inhibitor with IC50 of 102.3 nM, >100-fold selectivity over other methyltransferases.
903576-44-3Pitolisant hydrochloridePitolisant, also known as Tiprolisant, BF2649 and Ciproxidine, is a histamine receptor inverse agonist/antagonist selective for the H3 subtype. It has stimulant and nootropic effects in animal studies, and may have several medical applications, having been researched for the treatment of narcolepsy, for which it has been granted orphan drug status in the EU and US. It is currently in clinical trials for schizophrenia and Parkinson's disease. Pitolisant was the first clinically used H3 receptor inverse agonist.
269718-83-4SLV-308 hydrochloridePardoprunox is dopamine D2/5-HT1A receptor agonist potentially for the treatment of Parkinson's disease. It was also being investigated for the treatment of depression and anxiety but these indications appear to have been abandoned. Pardoprunox acts as a D2 (pKi = 8.1) and D3 receptor (pKi = 8.6) partial agonist (IA = 50% and 67%, respectively) and 5-HT1A receptor (pKi = 8.5) full agonist (IA = 100%). It also binds to D4 (pKi = 7.8), α1-adrenergic (pKi = 7.8), α2-adrenergic (pKi = 7.4), and 5-HT7 receptors (pKi = 7.2) with lower affinity.

First Previous Next End   Jump to  Page
PI3K/Akt/mTOR
Cell Cycle/Checkpoint
Angiogenesis/Tyrosine Kinase
Apoptosis Pathway
PARP/BET
Aurora/Ksp Pathway
MAPK Pathway
Hormone Pathay
Integrase/CCR5
Proteases/HSP90/HSP70 Pathway
Wnt/Hedgehog/Notch Pathway
Jak/Stat Pathway
Ca/cAMP/Lipid Signaling Pathway
Neuro Signaling Pathway
TGF-beta/Smad Signaling Pathway
GPCR Pathway
Ion channel Pathway
Cytochrome P450 Pathway
Others Pathway
Intermediate